The Evolution of Payer Access: Now and Then

Patients already look beyond their prescription benefits for ways to pay. The Inflation Reduction Act is likely to increase demand for new solutions. PRECISIONvalue Chief Medical Officer Dominic Galante explains why.

LEARN MORE

The Evolution of Payer Access: Now and Then2023-07-18T15:49:22-04:00

Part 2: Patient Affordability After the IRA: Potential Impacts

The Inflation Reduction Act (IRA) of 2022 contains a number of health care provisions, including those that will cut Medicare drug spending by an estimated $287 billion over 10 years, according to the congressional budget office. Some of the most widely discussed changes are several near-term changes to the Medicare Part D benefit that are some of the most significant changes in Medicare regulation since the Medicare Modernization Act of 2003. In this free brief (part 2 of 5), PRECISIONvalue expert Ryan Cox outlines how these cuts may impact access and affordability for all.

LEARN MORE

Part 2: Patient Affordability After the IRA: Potential Impacts2023-11-06T12:33:17-05:00

Part 1: The Growing Emergence of Biosimilars

Biosimilars are on track to reduce drug costs by $100 billion—but not everyone is on board. The Inflation Reduction Act has provisions that encourage their uptake. Get the details from PRECISIONvalue expert Amy Martin in this free brief (part 1 of 5).

LEARN MORE

Part 1: The Growing Emergence of Biosimilars2023-11-06T12:25:39-05:00